Whole-genome sequencing and genetic risk interpretation

Companies market genetic tests with confidence that science hasn't earned yet.

Understanding which variants are inherited versus acquired shapes every screening decision.

Other inherited cancer genes rival BRCA mutations in clinical importance and screening impact.

Genetic variants of uncertain significance affect one in three patients, often for years.

Genetic risk scores work best for patients standard calculators can't confidently categorize.

Exome sequencing offers better odds and lower costs for healthy adults without genetic red flags.

Health systems are shifting genetic drug testing from reactive fix to preventive habit.